No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
VRTX250117P450000
- 37.75
- +4.85+14.74%
15min DelayClose Jan 14 16:00 ET
37.75High37.04Low
37.04Open32.90Pre Close141 Volume685 Open Interest450.00Strike Price532.20KTurnover73.91%IV-0.14%PremiumJan 17, 2025Expiry Date38.34Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9196Delta0.0059Gamma10.51Leverage Ratio-0.5927Theta-0.0232Rho-9.67Eff Leverage0.0516Vega
Intraday
- 5D
- Daily
News
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio With Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $520
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $575